The field of drug harm reduction has achieved significant successes over several decades by focusing on mitigating the most immediate and life-threatening risks associated with drug use. These include preventing overdose deaths through the provision of naloxone and safe injection sites, combating the spread of blood-borne viruses like HIV and Hepatitis C via sterile needle exchange programs, and ensuring a safer drug supply through testing and information dissemination. However, a recent analysis suggests that this established framework may have a significant blind spot when it comes to the use of anabolic steroids. While often not classified as 'recreational' drugs in the same vein as opioids or stimulants, anabolic steroids carry their own set of serious health risks, and their use is often clandestine and unregulated, mirroring many of the challenges faced by other drug-using populations. The argument put forth is that the current harm reduction strategies, while effective for their intended targets, have largely overlooked the unique challenges and risks associated with anabolic steroid use. This includes a lack of accessible information on safe dosing, potential side effects, long-term health consequences, and strategies for managing withdrawal or addiction. Users of anabolic steroids may not engage with traditional harm reduction services due to stigma, lack of awareness, or the perception that their drug use falls outside the scope of current interventions. This oversight creates a vulnerability for individuals using these substances, potentially leading to severe health complications that could have been mitigated with appropriate harm reduction measures. The article advocates for an expansion of harm reduction principles to encompass the use of anabolic steroids, suggesting the development of tailored resources and outreach programs. This could involve providing accurate information about the risks and benefits, offering guidance on safer injection practices, and facilitating access to healthcare professionals who are knowledgeable about steroid-induced health issues. Furthermore, it highlights the need for a broader understanding of 'drug use' within harm reduction discourse, acknowledging that the motivations and patterns of use for substances like anabolic steroids differ from those of illicit street drugs, but the underlying principle of minimizing harm remains equally valid. By addressing this blind spot, harm reduction efforts can become more comprehensive and inclusive, ultimately saving more lives and improving the health outcomes for a wider range of individuals engaging in drug use.